Multinational comparison of diagnostic clues for uterine cervical lesions among cytotechnologists in Asian countries

Diagnostic Cytopathology

Volumn 39, Issue 7, 2011, Pages 489-494

  Taniyama, Kiyomi ^a   Jhala, Darshana N ^b   Katayama, Hironori ^c   Kuraoka, Kazuya ^a   Naito, Zenya ^c   Rangdaeng, Samreung ^d   Gong, Gyungyub ^e   Lai, Chiung Ru ^f   Chang, Alexander ^g   Jhala, Nirag C ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d Faculty of Medicine Chiang Mai University   (Thailand)

^e University of Ulsan College of Medicine   (South Korea)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

human papillomavirus; liquid based cytology; The Bethesda system; uterine cervix; vote

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL PRACTICE; CYTOTECHNOLOGIST; FEMALE; HUMAN; HUMAN TISSUE; JAPANESE; MALE; PAPANICOLAOU TEST; PRIORITY JOURNAL; SQUAMOUS CELL; UTERINE CERVIX CANCER;

ASIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79959599775     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21418     Document Type: Article

References (10)

1. Narisawa-Saito M, Kiyono T,. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci 2007; 98: 1505-1511. (Pubitemid 47308443)
2. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M,. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008; 113 (7 Suppl): 1980-1993.
3. Miyashita M, Agdamag DM, Sasagawa T, et al. High-risk HPV types in lesions of the uterine cervix of female commercial sex workers in the Philippines. J Med Virol 2009; 81: 545-551.
4. Jenkins D,. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008; 110 (Suppl 1): S18-S25.
5. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
6. Konno R, Shin HR, Kim YT, et al. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine 2008; 26 (Suppl 12): M30-M42.
7. Garland SM, Cuzick J, Domingo EJ, et al. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2008; 26 (Suppl 12): M89-M98.
8. Hutchinson ML, Isenstein LM, Goodman A, et al. Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor. Am J Clin Pathol 1994; 101: 215-219. (Pubitemid 24061451)
9. Solomon D, Nayar R,. The Bethesda system for reporting cervical cytology. New York: Springer-Verlag; 2004.
10. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-1772. (Pubitemid 350137476)